# Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer

> **NCT00567554** · PHASE3 · COMPLETED · sponsor: **GBG Forschungs GmbH** · enrollment: 2600 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** epirubicin - cyclophosphamide / docetaxel
- **DRUG:** epirubicin - cyclophosphamide / docetaxel + bevacizumab
- **DRUG:** paclitaxel
- **DRUG:** paclitaxel + everolimus (RAD001)
- **DRUG:** epirubicin - cyclophosphamide / docetaxel + trastuzumab
- **DRUG:** epirubicin - cyclophosphamide / docetaxel + lapatinib

## Key facts

- **NCT ID:** NCT00567554
- **Lead sponsor:** GBG Forschungs GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2011-08
- **Final completion:** 2015-10
- **Target enrollment:** 2600 (ACTUAL)
- **Last updated:** 2016-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00567554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00567554, "Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00567554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*